Safety and Immunogenicity of Sanofi Pasteur’s DTaP-IPV-Hep B-PRP-T Combined Vaccine Given as a Primary Series of Vaccination in Infants

Mise à jour : Il y a 4 ans
Référence : U1111-1143-8252

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To describe the safety and reactogenicity after each and all doses of the study vaccine administered as a 3-dose primary series.


Critère d'inclusion

  • Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus influenzae type b and infection caused by hepatitis B virus

Liens